The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants. This innovative treatment is poised to change the landscape of depression management, particularly for those grappling with treatment-resistant depression (TRD).
